|
1
|
Koshy M, Greenwald BD, Hausner P, Krasna
MJ, Horiba N, Battafarano RJ, Burrows W and Suntharalingam M:
Outcomes after trimodality therapy for esophageal cancer: The
impact of histology on failure patterns. Am J Clin Oncol.
34:259–264. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Cooper JS, Guo MD, Herskovic A, Macdonald
JS, Martenson JA Jr, Al-Sarraf M, Byhardt R, Russell AH, Beitler
JJ, Spencer S, et al: Chemoradiotherapy of locally advanced
esophageal cancer: Long-term follow-up of a prospective randomized
trial (RTOG 85-01). Radiation Therapy Oncology Group. JAMA.
281:1623–1627. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Minsky BD, Pajak TF, Ginsberg RJ, Pisansky
TM, Martenson J, Komaki R, Okawara G, Rosenthal SA and Kelsen DP:
INT 0123 (Radiation Therapy Oncology Group 94–05) phase III trial
of combined-modality therapy for esophageal cancer: High-dose
versus standard-dose radiation therapy. J Clin Oncol. 20:1167–1174.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Shapiro J, van Lanschot JJ, Hulshof MC,
van Hagen P, van Berge Henegouwen MI, Wijnhoven BP, van Laarhoven
HW, Nieuwenhuijzen GA, Hospers GA, Bonenkamp JJ, et al: Neoadjuvant
chemoradiotherapy plus surgery versus surgery alone for oesophageal
or junctional cancer (CROSS): Long-term results of a randomised
controlled trial. Lancet Oncol. 16:1090–1098. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Van Hagen P, Hulshof MC, van Lanschot JJ,
Steyerberg EW, van Berge Henegouwen MI, Wijnhoven BP, Richel DJ,
Nieuwenhuijzen GA, Hospers GA, Bonenkamp JJ, et al: Preoperative
chemoradiotherapy for esophageal or junctional cancer. N Engl J
Med. 366:2074–2084. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Tepper J, Krasna MJ, Niedzwiecki D, Hollis
D, Reed CE, Goldberg R, Kiel K, Willett C, Sugarbaker D and Mayer
R: Phase III trial of trimodality therapy with cisplatin,
fluorouracil, radiotherapy, and surgery compared with surgery alone
for esophageal cancer: CALGB 9781. J Clin Oncol. 26:1086–1092.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hoeppner J, Zirlik K, Brunner T, Bronsert
P, Kulemann B, Sick O, Marjanovic G, Hopt UT and Makowiec F:
Multimodal treatment of locally advanced esophageal adenocarcinoma:
Which regimen should we choose? Outcome analysis of perioperative
chemotherapy versus neoadjuvant chemoradiation in 105 patients. J
Surg Oncol. 109:287–293. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ford HE, Marshall A, Bridgewater JA,
Janowitz T, Coxon FY, Wadsley J, Mansoor W, Fyfe D, Madhusudan S,
Middleton GW, et al: Docetaxel versus active symptom control for
refractory oesophagogastric adenocarcinoma (COUGAR-02): An
open-label, phase 3 randomised controlled trial. Lancet Oncol.
15:78–86. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Laskar SG, Lewis S, Agarwal JP, Mishra S,
Mehta S and Patil P: Combined brachytherapy and external beam
radiation: An effective approach for palliation in esophageal
cancer. J Contemp Brachytherapy. 7:453–461. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Rabenstein T: Palliative endoscopic
therapy of esophageal cancer. Viszeralmedizin. 31:354–359. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Kim YS, Lee CG, Kim KH, Kim T, Lee J, Cho
Y and Koom WS: Re-irradiation of recurrent esophageal cancer after
primary definitive radiotherapy. Radiat Oncol J. 30:182–188. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ilson DH: Esophageal cancer chemotherapy:
Recent advances. Gastrointest Cancer Res. 2:85–92. 2008.PubMed/NCBI
|
|
13
|
Crane CH: Hypofractionated ablative
radiotherapy for locally advanced pancreatic cancer. J Radiat Res.
57:(Suppl 1). i53–i57. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Pontoriero A, Iatì G, Aiello D and
Pergolizzi S: Stereotactic radiotherapy in the retreatment of
recurrent cervical cancers, assessment of toxicity, and treatment
response: Initial results and literature review. Technol Cancer Res
Treat. 15:759–765. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Paddick I and Lippitz B: A simple dose
gradient measurement tool to complement the conformity index. J
Neurosurg. 105:(Suppl). S194–S201. 2006.
|
|
16
|
International Commission on Radiation
Units and Measurements, . Prescribing, Recording and Reporting
Intensity-Modulated Photon-Beam Therapy (IMRT) (ICRU Report 83). J
ICRU. 10:1–10618. 2010.
|
|
17
|
Brierley JD, Gospodarowicz MK and
Wittekind C: TNM Classification Of Malignant Tumours. 7th.
Wiley-Blackwell; pp. 62–66. 2009
|
|
18
|
Mizota A, Shitara K, Kondo C, Nomura M,
Yokota T, Takahari D, Ura T and Muro K: A retrospective comparison
of docetaxel and paclitaxel for patients with advanced or recurrent
esophageal cancer who previously received platinum-based
chemotherapy. Oncology. 81:237–242. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wilke H, Muro K, Van Cutsem E, Oh SC,
Bodoky G, Shimada Y, Hironaka S, Sugimoto N, Lipatov O, Kim TY, et
al: Ramucirumab plus paclitaxel versus placebo plus paclitaxel in
patients with previously treated advanced gastric or
gastro-oesophageal junction adenocarcinoma (RAINBOW): A
double-blind, randomised phase 3 trial. Lancet Oncol. 15:1224–1235.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Bang YJ, Van Cutsem E, Feyereislova A,
Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T,
et al: Trastuzumab in combination with chemotherapy versus
chemotherapy alone for treatment of HER2-positive advanced gastric
or gastro-oesophageal junction cancer (ToGA): A phase 3,
open-label, randomised controlled trial. Lancet. 376:687–697. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kirichenko A, Gayou O, Parda D,
Kudithipudi V, Tom K, Khan A, Abrams P, Szramowski M, Oliva J,
Monga D, et al: Stereotactic body radiotherapy (SBRT) with or
without surgery for primary and metastatic liver tumors. HPB
(Oxford). 18:88–97. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Matzenauer M, Vrana D, Vlachova Z,
Cwiertka K, Kalita O and Melichar B: Radiotherapy management of
brain metastases using conventional linear accelerator. Biomed Pap
Med Fac Univ Palacky Olomouc Czech Repub. 160:412–416.
2016.PubMed/NCBI
|
|
23
|
Vrána D, Študentová H, Matzenauer M,
Vlachová Z, Cwierka K, Gremlica D and Kalita O: Treatment of brain
metastases of renal cell cancer with combined hypofractionated
stereotactic radiotherapy and whole brain radiotherapy with
hippocampal sparing. Oncology Lett. 11:3777–3781. 2016.
|
|
24
|
Santeufemia DA, Tumolo S, De Paoli A, Lo
Re G, Boz G, Miolo GM, Baresic T, Basso SM and Innocente R:
Chemo/tomotherapy stereotactic body radiation therapy (chemo/SBRT)
for the salvage treatment of esophageal carcinoma following
trimodality therapy: A case report. Tumori. 98:143e–145e.
2012.PubMed/NCBI
|
|
25
|
Russo JK and Rosen L: TomoTherapy
stereotactic body radiation therapy (SBRT) for the salvage
treatment of locally recurrent esophageal adenocarcinoma following
trimodality therapy: A case report. Tumori. 97:406–410.
2011.PubMed/NCBI
|
